Photo

Photo detail

Marty Duvall

Stories this photo appears in:

Tocagen to Conduct ‘Operational Review’ After Clinical Trial

Biotech’s Brain Cancer Treatment Posts Disappointing Results

In 2017, Tocagen raised $87 million in a public offering. Investors saw potential in the San Diego biotech’s combo treatment for recurrent brain cancer.